ESTRO 2025 - Abstract Book

S235

Brachytherapy - Gynaecology

ESTRO 2025

Figure 1.

Conclusion: EBT achieved the dose constraints in most cases and was well tolerated by the patients. Patients without distant progression achieved excellent local control in the uterine cervix. Further studies will be of great value in finding the benefits of EBT in cervical cancer. This study is financed by the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, project № BG-RRP-2.004-0003-C01.

Keywords: cervical cancer, electronic brachytherapy

1689

Proffered Paper Transitioning from CTVHR D90% to CTVHR D98% brachytherapy dose prescription in the RAPID prospective clinical study for favorable-risk cervical cancer Monica F. Serban 1,2 , Remi Nout 3 , Sofia Spampinato 3 , Kathy Han 1,2 , Inger-Karine Kolkman-Deurloo 3 , Henrike Westerveld 3 , Fleur Huang 4 , Kathrin Kirchheiner 5 , Marianne Assenholt 6 , Kjersti Bruheim 7 , Cyrus Chargari 8 , Pittaya Dankulchai 9 , Taran Paulsen Hellebust 10 , Jeevanshu Jain 11 , Linda Rossi 3 , Barbara Segedin 12 , Yvette Seppenwoolde 3 , Li Tee Tan 13 , Margit Valgma 14 , Laura Velema 15 , Ericka Wiebe 4 , Prachi Mittal 16 , Supriya Chopra 11 , Kari Tanderup 6,17 1 Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada. 2 Radiation Oncology, University of Toronto, Toronto, Canada. 3 Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4 Oncology, Cross Cancer Institute, and University of Alberta, Edmonton, Canada. 5 Radiation Oncology, Comprehensive Cancer Center, General Hospital Vienna, Medical University of Vienna, Vienna, Austria. 6 Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark. 7 Oncology, Oslo University Hospital, Oslo, Norway. 8 Radiotherapy, Pitié Salpêtrière University Hospital, APHP, Sorbonne University, Paris, France. 9 Radiology, Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,, Thailand. 10 Medical Physics, Oslo University Hospital, Oslo, Norway. 11 Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India. 12 Radiotherapy, Institute of Oncology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 13 Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. 14 Radiotherapy, North Estonia Medical Centre Foundation, Tallinn, Estonia. 15 Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands. 16 Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute,, Mumbai, India. 17 Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark Purpose/Objective: To evaluate the feasibility of a new brachytherapy (BT) dose prescription protocol transitioning from CTV HR D90% to D98% within the Response Adapted Precise and Individualised radiotherapy Dose prescription in favourable risk locally advanced cervical cancer (RAPID) study for favorable-risk cervical cancer.